Checkpoint inhibitors against CTLA-4 (Dias et al., 2011) and PD-L1 (Wang et al., 2020) have been cloned into oncolytic adenoviruses and have shown to be effective in controlling tumor growth with a high safety profile. The gene discussed is CTLA4; the disease is neoplasm.